Insulet Corporation
$7.2M 17,948 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Solventum Corporation
Solventum Corporation reported $7,126,093.05 across General Payments, Research, and Ownership to 24,481 physicians and teaching hospitals across 24,559 transactions.
- $7.1M
- All-tracks total
- 24,559
- Transactions
- 24,481
- Recipients
- #219
- of 1,925 companies
Solventum Corporation reported $7,126,093.05 across all CMS Open Payments tracks (General + Research + Ownership) to 24,481 physicians and teaching hospitals in Program Year 2024 - ranking #219 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $6,022,060.49, averaging $291.09 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer solventum-corporation Solventum Corporation
$7.1M · #219/1,925 · 0.1% industry · PY2024
- TOT $7.1M
- RANK #219
- SHARE 0.1%
- TXN 24,559
- RCP 24,481
- CAT 14
- GEN $6.0M
- TOP1 10.9%
- PY 2024
Volume peers
Nearest volume peer: Insulet Corporation ($7.2M)
Solventum Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Solventum Corporation
$7,126,093.05: that is what Solventum Corporation reported in payments to 24,481 physicians and teaching hospitals during Program Year 2024, spread across 24,559 transactions ($290.16 per transaction, $291.09 per recipient). The company sits at rank #219 of 1,925, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.
The 14-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Grant" at $1.8M, accounting for 29.5% of this company's General Payments and 34 transactions.
General Payment Breakdown by Type
Across 14 types of general payments, Solventum Corporation's largest category was "Grant" at $1.8M - 29.5% of General Payments.
Solventum Corporation reports 14 general-payment categories - the top three are Grant (29.5%), Compensation for Services Other Than Consulting (26.1%), and Consulting Fee (13.7%). The remaining 11 categories make up 30.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Solventum Corporation files across 14 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Solventum Corporation divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Grant | $1.8M | 34 | 29.5% |
| Compensation for Services Other Than Consulting | $1.6M | 287 | 26.1% |
| Consulting Fee | $824.9K | 428 | 13.7% |
| Food and Beverage | $795.4K | 22,417 | 13.2% |
| Travel and Lodging | $485.7K | 1,225 | 8.1% |
| Compensation for Faculty or Speaker (Medical Education) | $170.2K | 30 | 2.8% |
| Royalty or License | $154.1K | 4 | 2.6% |
| Long-Term Medical Supply or Device Loan | $116.8K | 4 | 1.9% |
| Space Rental or Facility Fees | $73.3K | 2 | 1.2% |
| Honoraria | $46.4K | 10 | 0.8% |
| Debt Forgiveness | $3.8K | 18 | 0.1% |
| Education | $3.1K | 7 | 0.1% |
| Entertainment | $702.79 | 14 | 0.0% |
| Gift | $87.79 | 1 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,824,258.04 (30.3%) of $6,022,060.49 in this company's General Payments records across 17,026 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Solventum Corporation
The five named recipients with the highest reported General Payments from this company
- 1
University Of Iowa Hosp & Clinics
$654,750.00 across 2 reported transactions
- 2
Board Of Trustees Of The University
$540,999.24 across 1 reported transactions
- 3
Donna J Stenberg
$242,236.83 across 30 reported transactions
- 4
Univ Of Mi Hospitals & Hlth Ctrs
$235,585.97 across 1 reported transactions
- 5
Maimonides Medical Center
$150,686.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Solventum Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Solventum Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Solventum Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Neurology Practice Consortium Gpo, LLC
$7.0M 0 recipients
Compare payment profiles
Woven Orthopedic Technologies, LLC
$7.0M 11 recipients
Compare payment profiles
Dompe Farmaceutici S.p.A.
$6.9M 7 recipients
Compare payment profiles
Astellas Pharma Inc
$6.9M 81 recipients
Compare payment profiles
Astellas US Technologies
$6.9M 0 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.